Nkarta News

Express News | Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.d., Facr, to Board of Directors

ReutersJun 13 16:01 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: Deciphera Pharmaceuticals (DCPH), Atara Biotherapeutics (ATRA) and Nkarta (NKTX)

TipRanksMay 15 22:10 ET

EnGene Holdings: Nkarta's Paul Hastings and Forbion's Wouter Joustra Elected to Bd >ENGN

EnGene Holdings: Nkarta's Paul Hastings and Forbion's Wouter Joustra Elected to Bd >ENGN

Dow JonesMay 15 16:17 ET

Nkarta Price Target Raised to $23.00/Share From $22.00 by HC Wainwright & Co.

Nkarta Price Target Raised to $23.00/Share From $22.00 by HC Wainwright & Co.

Dow JonesMay 13 13:56 ET

Nkarta Is Maintained at Buy by Needham

Nkarta Is Maintained at Buy by Needham

Dow JonesMay 13 13:44 ET

Express News | Needham Maintains Buy on Nkarta, Lowers Price Target to $13

BenzingaMay 13 13:33 ET

Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans

Yahoo FinanceMay 11 08:14 ET

Nkarta Inc (NKTX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Analysis

Yahoo FinanceMay 10 14:56 ET

Nkarta Is Maintained at Buy by Canaccord Genuity

Nkarta Is Maintained at Buy by Canaccord Genuity

Dow JonesMay 10 14:50 ET

Express News | Canaccord Genuity Maintains Buy on Nkarta, Lowers Price Target to $15

BenzingaMay 10 14:40 ET

Nkarta Inc. Buy Rating Affirmed Amidst Promising Clinical Studies and Robust Financial Health

TipRanksMay 10 06:35 ET

Express News | Nkarta Inc : Needham Cuts Target Price to $13 From $15

ReutersMay 10 06:28 ET

Buy Rating Affirmed: Nkarta's NKX019 Shows Promise in Lupus Nephritis Clinical Trials

TipRanksMay 10 06:28 ET

William Blair Remains a Buy on Nkarta (NKTX)

TipRanksMay 9 21:55 ET

Nkarta | 10-Q: Quarterly report

SEC announcementMay 9 16:57 ET · Announcements

Nkarta Q1 2024 GAAP EPS $(0.58) Misses $(0.57) Estimate, Cash Balance $450M

Nkarta Q1 2024 GAAP EPS $(0.58) Misses $(0.57) Estimate, Cash Balance $450M

BenzingaMay 9 16:51 ET

Nkarta: Current Cash and Cash Equivalents Will Be Sufficient to Fund Its Current Operating Plan Into Late 2027

Nkarta: Current Cash and Cash Equivalents Will Be Sufficient to Fund Its Current Operating Plan Into Late 2027

Dow JonesMay 9 16:12 ET

Express News | Nkarta Q1 Cash & Investments USD 450 Million

ReutersMay 9 16:01 ET

Nkarta 1Q Loss/Shr 58c >NKTX

Nkarta 1Q Loss/Shr 58c >NKTX

Dow JonesMay 9 16:01 ET

Express News | Nkarta Q1 Net Income USD -29.518 Million

ReutersMay 9 16:01 ET